Hancock Jaffe Laboratories Incの将来のP / E
Hancock Jaffe Laboratories Incの将来のP / Eは何ですか。
Hancock Jaffe Laboratories Incの将来のP / Eは-6.70です。
将来のP / Eの定義は何ですか。
未来比率P / E (株価収益率)は、企業の株価と今後12ヶ月間の1株当たり利益見込額との比率です。
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
NASDAQのセクタHealth Careにおける将来のP / Eの企業と比べるHancock Jaffe Laboratories Inc
Hancock Jaffe Laboratories Incは何をしますか。
Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValveÒ, a porcine-based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, and the CoreoGraftÒ, a bovine tissue-based off-the-shelf conduit intended to be used for coronary artery bypass surgery.
Hancock Jaffe Laboratories Incと類似の将来のp / e
- Focus Incの将来のP / Eは-6.86です。
- Zevra Therapeutics Incの将来のP / Eは-6.83です。
- RiceBran Technologiesの将来のP / Eは-6.78です。
- Digirad Corpの将来のP / Eは-6.77です。
- Cynata Therapeuticsの将来のP / Eは-6.77です。
- Mustang Bio Incの将来のP / Eは-6.76です。
- Hancock Jaffe Laboratories Incの将来のP / Eは-6.70です。
- Aqua Metals Incの将来のP / Eは-6.67です。
- Biocryst Pharmaceuticalsの将来のP / Eは-6.67です。
- OptiNose Incの将来のP / Eは-6.64です。
- Citius Pharmaceuticals Incの将来のP / Eは-6.64です。
- Replimune Incの将来のP / Eは-6.61です。
- Celcuity Incの将来のP / Eは-6.59です。